Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea and Vomiting Chemotherapy-Induced Clear all
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

NCT00404378
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ketoconazole, casopitant 100 mg, Casopitant 50 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Jul 23, 2026, 10:04 AM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Not applicable Interventional Results available

The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients

NCT01996410
View directory record Official record
Conditions
Breast Cancer Stages I Through III
Interventions
Acupuncture
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 23, 2026, 10:04 AM EDT
Not listed Phase 4 Interventional

Safety Study of Repeat Doses of SUSTOL in Adults

NCT05434663
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
SUSTOL
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Hattiesburg, Mississippi • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

NCT00636805
View directory record Official record
Conditions
Brain Cancer
Interventions
Palonosetron (Aloxi) and Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

NCT01736917
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Fosaprepitant, Dexamethasone, 5HT3
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
15 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • St Louis, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851
View directory record Official record
Conditions
Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions
LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Ginger Control of Chemotherapy Induced Nausea and Vomiting

NCT00065221
View directory record Official record
Conditions
Nausea, Vomiting, Chemotherapy
Interventions
Ginger
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jul 23, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

NCT00418678
View directory record Official record
Conditions
Nausea and Vomiting
Interventions
Cesamet
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

NCT01500226
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

NCT01442376
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jul 23, 2026, 10:04 AM EDT
Not listed No phase listed Observational

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

NCT02016807
View directory record Official record
Conditions
Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions
ProThelial
Device
Lead sponsor
Ashley Downs Bioscience
Industry
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Foster, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

NCT01450826
View directory record Official record
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Olanzapine, Aprepitant
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984
View directory record Official record
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

NCT00440128
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Docetaxel, Casopitant/Docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

NCT04592198
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
Drug
Lead sponsor
Xiamen LP Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Anaheim, California • Ocala, Florida • Skokie, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 23, 2026, 10:04 AM EDT